## Correct Answer: B. Lead time bias Lead time bias occurs when earlier detection of disease (through screening) advances the time of diagnosis without actually changing the time of death, artificially inflating survival time. In this scenario, breast cancer screening detects tumours earlier in their natural history. The 5-year survival rate improves because patients are now counted as "survivors" for a longer period from diagnosis to death—even though they die at the same absolute time as unscreened patients. The autopsy data showing no change in mortality is the critical clue: it proves that screening did not reduce actual deaths, only shifted the diagnosis earlier. This is the hallmark of lead time bias. The screening programme appears beneficial (improved survival statistics) when it is merely advancing the point at which disease is detected. In Indian public health screening programmes (e.g., district-level breast cancer initiatives), this bias is a common pitfall when evaluating screening effectiveness using survival metrics alone rather than mortality rates. Park's textbook emphasizes that **mortality rate** (not survival rate) is the gold standard for assessing screening efficacy. ## Why the other options are wrong **A. Berksonian bias** — Berksonian bias is a selection bias that occurs in hospital-based studies when two diseases are independently associated with hospitalization, creating a spurious negative correlation in the hospital sample. It has no relevance to screening programmes or the discrepancy between survival and mortality rates. This is a distractor that tests knowledge of bias types but does not fit the clinical scenario. **C. Survival bias** — Survival bias (or survivor bias) refers to the error of focusing only on successful cases while ignoring failures, leading to false conclusions about efficacy. While related to survival outcomes, it does not explain why autopsy mortality remains unchanged despite improved survival statistics. Survival bias is about incomplete data collection, not about the timing of diagnosis versus death. **D. Detection bias** — Detection bias occurs when a screening test detects more cases of disease (increasing incidence) but does not reflect true disease burden—often due to increased sensitivity. While screening does detect more cases, detection bias alone does not explain the specific pattern of improved survival with unchanged mortality. Lead time bias is the precise mechanism linking earlier diagnosis to apparent (but not real) survival improvement. ## High-Yield Facts - **Lead time bias** = earlier diagnosis without change in time of death → artificially prolonged survival time. - **Mortality rate** (not survival rate) is the gold standard for evaluating screening programme efficacy in public health. - Autopsy data showing unchanged mortality despite improved survival statistics is pathognomonic for lead time bias. - In Indian district-level screening programmes, survival metrics must always be validated against mortality data to avoid false claims of benefit. - Lead time bias is independent of screening sensitivity or specificity; it reflects the natural history of disease detection timing. ## Mnemonics **LEAD = Longer Elapsed time from diagnosis, Actual death unchanged** Lead time bias advances the diagnosis date (LEAD) but the patient dies at the same absolute time. Survival time increases on paper only. Use this when you see: improved survival + unchanged mortality. **Screening Bias Hierarchy: Lead > Detection > Survival** Lead time (diagnosis timing) → Detection (case finding) → Survival (outcome measurement). Lead time bias is the most common in screening evaluation. Remember: mortality is immune to lead time bias; survival is not. ## NBE Trap NBE pairs "improved survival" with "screening benefit" to lure students into choosing detection bias or survival bias. The critical discriminator is the autopsy finding (unchanged mortality), which isolates lead time bias as the only mechanism that explains the paradox. ## Clinical Pearl In Indian district-level cancer screening programmes (e.g., NRHM-supported breast cancer initiatives), improved 5-year survival rates are often cited as programme success. However, without mortality data, these claims may reflect lead time bias rather than true benefit. Always audit screening programmes using mortality reduction, not survival time, as the endpoint. _Reference: Park's Textbook of Preventive and Social Medicine, Ch. 9 (Screening); Robbins & Cotran Pathologic Basis of Disease, Ch. 1 (Epidemiology)_
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.